BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 5, 2004
View Archived Issues
ODAC In Favor Of Safety Trials For Amgen, J&J EPO Products
GAITHERSBURG, Md. - The Oncologic Drugs Advisory Committee generally agreed that it is reasonable to ask makers of Aranesp and Procrit to conduct placebo-controlled trials to assess possible adverse events. (BioWorld Today)
Read More
Acologix's Series B Pulls Down $39.6M For Bone Drug Phase II
Read More
Microbia Completes $40M Round As Lead Compounds Near Clinic
Read More
Merrimack Raises $28M To Fund Development Of Network Biology
Read More
Serono Secures Rights To 4SC Program In Autoimmune Disease
Read More
Axonyx Brings In Another $20M Through Sale Of Stock, Warrants
Read More
Other News To Note
Read More